乙型肝炎后肝硬化患者接受核苷类抗病毒药物治疗的临床效果

Clinical effect of nucleoside antiviral drugs in the treatment of hepatitis B cirrhosis

目的分析乙型肝炎后肝硬化患者接受核苷类抗病毒药物治疗的临床效果。方法将我院2014年7月至2016年1月收治的120例乙型肝炎后肝硬化患者随机分为拉米夫定组、阿德福韦酯组、恩替卡韦组,分别给予拉米夫定、阿德福韦酯、恩替卡韦治疗,每组40例。比较三组患者的临床治疗效果。结果治疗后,三组患者的谷丙转氨酶、谷草转氨酶、总胆红素、清蛋白、凝血酶原时间活动度水平明显优于治疗前(P<0.05),但三组间比较,差异无统计学意义(P>0.05)。拉米夫定组不良反应总发生率为10.0%,恩替卡韦组不良反应总发生率12.5%,阿德福韦酯组不良反应总发生率为7.5%,差异无统计学意义(P>0.05)。结论核苷类抗病毒药物治疗乙型肝炎后肝硬化效果理想,安全性高,值得作为临床治疗的优选方案进行推广使用。

Objective To analyze the clinical effect of nucleoside antiviral drugs in the treatment of hepatitis B cirrhosis.Methods A total of 120 hepatitis B cirrhosis patients admitted in our hospital from July 2014 to January 2016 were selected and randomly divided into lamivudine group, adefovir dipivoxil group and entecavir group, the three groups were treated with lamivudine, adefovir dipivoxil and entecavir respectively, with 40 cases in each group. The clinical effects of the three groups were compared. Results After treatment, the levels of glutamic-pyruvic transaminase, gutamic oxalacetic transaminase, total bilirubin, albumin and prothrombin time activity of the three groups were better than those before treatment（P〈0.05）, but there were no significant differences among the three groups（P〈0.05）. The incidence of adverse reactions of the lamivudine group was 10.0%, that of the adefovir dipivoxil group was 12.5%, and that of the entecavir group was 7.5%,there were no significant differences among the three groups（P〈0.05）. Conclusion Nucleoside antiviral drugs has remarkable clinical effect in the treatment of hepatitis B cirrhosis, it has high safety, which is worthy of popularization and application as the best choice of clinical treatment.